NORTHLAND

NORTHLAND

Language

NORTHLAND NL005 Phase II clinical trial has successfully completed enrollment of all subjects.

发布时间：2023-03-01

On March 1, 2023, our company successfully completed the enrollment of all subjects in the Phase II clinical trial for NL005—the project code for our independently developed Class 1 innovative drug, “Recombinant Human Thymosin β4 Injection”—which is intended for the treatment of ischemia-reperfusion injury in acute myocardial infarction.

20

2023-02

The Beijing Stock Exchange’s market-making trading service has officially launched—our company is among the first batch of securities designated for market making.

发布时间：2023-02-20

On February 20, 2023, the Beijing Stock Exchange launched stock market-making trading services, officially implementing a hybrid trading system that combines auction trading with market-making trading. The first batch included a total of 13 securities firms participating in market-making, covering 36 stocks designated for market making. NORTHLAND was listed among the first batch of stocks eligible for market making.

11

2023-02

WelcomiNORTHLAND Selected as One of the First Batch of Stocks Eligible for Margin Trading and Short Selling

发布时间：2023-02-11

On February 10, 2023, the Beijing Stock Exchange announced that the margin trading and short selling (hereinafter referred to as "two-way margin trading") business would officially kick off on February 13. At that time, securities companies that have obtained the two-way margin trading access rights from the Beijing Stock Exchange will be able to accept investor mandates and submit two-way margin trading applications to the Beijing Stock Exchange. On the same day, the Beijing Stock Exchange issued the "Announcement on Matters Relating to the Scope of Stocks Eligible for Margin Trading and Short Selling," clarifying the criteria for including stocks in the list of eligible securities for two-way margin trading and announcing the first batch of eligible stocks. NORTHLAND was among those selected.

07

2023-02

NORTHLAND Signs Strategic Cooperation Agreement with Youjia Bio

发布时间：2023-02-07

On February 7, 2023, the company signed a strategic cooperation agreement with Youjia (Hangzhou) Biopharmaceutical Technology Co., Ltd. (hereinafter referred to as “Youjia Bio”). Guided by the principles of “innovative development and win-win cooperation,” the two parties will engage in deep strategic collaboration in areas such as the development of innovative gene-based drugs. They will pursue long-term cooperation in fields including delivery systems, plasmid DNA, and siRNA therapeutics, leveraging their respective strengths to jointly advance the development of gene therapies and achieve a mutually beneficial common goal.

19

2021-04

NORTHLAND: Pharmaceutical revenue is promising, R&D investment remains steady, and its science and technology innovation attributes continue to improve.

发布时间：2021-04-19

Beijing Northland Biotechnology Co., Ltd. (stock abbreviation: NORTHLAND, stock code 430047) recently released its 2020 annual report. The data show that during the reporting period, the company achieved operating revenue of 41.43286 million yuan, a year-on-year surge of 471.44%. Its subsidiary, Huonland, turned profitable during the reporting period, with annual operating revenue reaching 40.3177 million yuan and net profit amounting to 9.7781 million yuan. As a bio-innovative pharmaceutical company that advanced to the Select Tier under the fourth set of criteria—“market capitalization + R&D investment”—NORTHLAND has not yet commercialized its major newly developed drugs, and its operating performance remains in a state of loss.

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

Friendly Links: Baidu | NORTHLAND

NORTHLAND

Contact Information

Address: Room A406, Zhongguancun Biomedical Park, No. 5 Kaituo Road, Shangdi, Haidian District, Beijing

Hotline: +86 010-82890893

Email: northland@northland-bio.com

Website: www.northland-bio.com

Complaints Reporting Hotline: +86 010-82890893-8031

Complaints Reporting Email: pv@northland-bio.com

Follow Us

Northland is an innovative biopharmaceutical company specializing in the R&D, manufacturing and sales of gene therapy drugs, recombinant protein drugs and ophthalmic medications.

WeChat Mini Program

Web site

WeChat Official Account

NL-BIO

Scientific Research on Lower Limb Ischemia

NL003

Myocardial Infarction Scientific Research

NL005

Business license

Powered by 300.cn  Privacy Policy